Previous 10 | Next 10 |
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) PR Newswire Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy ...
Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration PR Newswire Presentations reinforce that aflibercept 8 mg demonstrated non-inferior vision gains to EYLEA at 48 weeks, with 93% and 83% of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way. However, when...
Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 a.m. ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief...
Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders PR Newswire First Phase 2 data for odronextamab (CD20xCD3) in diffuse large B-cell lymphoma and follicular lymphoma to be presented in two oral sessions ...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) Q3 revenues excluding COVID-19 therapies grew as blockbusters Eylea and Dupixent drove up sales. Q3 non-GAAP EPS declined -28% Y/Y to $11.14, while total revenue fell -15% Y/Y to $2.94B. Total revenues excluding COV...
Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q3 Non-GAAP EPS of $11.14 beats by $1.52 . Revenue of $2.94B (-14.8% Y/Y) beats by $80M . Third quarter 2022 EYLEA U.S. net sales increased 11% versus third quarter 2021 to a record $1.63 billi...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is $9.62 (-37.4% Y/Y) and the consensus Revenue Estimate is $2.86B (-17.1% Y/Y). Over the last 2 years, R...
Summary Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA approval, could increase EPS dramatically in future years. Strong ups...
Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award PR Newswire Inmazeb is the first FDA-approved treatment for Zaire ebolavirus TARRYTOWN, N.Y. , Oct. 28, 2022 ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...